Navigation Links
Frost & Sullivan Lauds U-Systems for Its Unique Technology and Strategic Excellence Paving the Way for Robust Growth

MOUNTAIN VIEW, Calif., Aug. 28, 2012 /PRNewswire/ -- Based on its recent analysis of the breast imaging market, Frost & Sullivan recognizes U-Systems, Inc. with the 2012 North American Frost & Sullivan Award for Entrepreneurial Company of the Year. The company has already won the 2011 Technology Innovation Award in the automated breast ultrasound (ABUS) market and has now received recognition for leveraging its unique products and demonstrating strategic excellence that has resulted in robust growth.

Approximately 40 percent of women in the United States have dense breast tissue, a condition for which studies suggest that up to 75 percent of cancers can go undetected through screening with X-ray mammography alone. While ultrasound has always been an effective adjunct to mammography, especially for women with dense breasts, its heavy dependence on operator expertise was a disadvantage. U-Systems' pioneering somo-v ® Automated Breast Ultrasound (ABUS) system addresses this and many other challenges to the standard deployment of ultrasound for breast imaging.

"Through its provision of an automated breast ultrasound solution that reduces breast ultrasound screening exam times while improving the accuracy of breast cancer detection in women with dense breast tissue, U-Systems addresses some of the biggest challenges in breast imaging today," said Frost & Sullivan Industry Analyst Roberto G. Aranibar. "As a result, U-Systems is on track for significant growth in 2012 and destined to become a key contender in the North American breast imaging equipment market."

U-Systems' somo-v ABUS system automates the breast ultrasound imaging process by providing 3D ultrasound images of breast tissue, making it an ideal imaging modality for a high-volume screening environment. Another differentiating feature of the system is its Reverse Curve™ Soft Touch transducer technology. Unlike conventional transducers, this one has a concave shape that enables a quicker, more comfortable breast exam, while improving imaging resolution and reducing artifacts. The system enables rapid review and archiving of patient exams, which optimizes the workflow of the screening process and allows the operator to select individual diagnostic planes, including a high-resolution coronal view, a feature that cannot be achieved on 2D ultrasound.

"By overcoming the ultrasound modality's limitations as an adjunctive to mammography, U-Systems has developed a technology that has the potential to emerge as a life-saving diagnostic aid that enables physicians to effectively diagnose the breast cancers missed by mammography," noted Aranibar. "Even given the recent controversies surrounding breast density and cancer risk, the company's commitment to investing in clinical research aimed at delivering this important breast cancer screening tool can not be understated."

For instance, the company completed a multi-center breast cancer screening clinical study to provide the evidence needed to support a new pre-market application (PMA) submission to the U.S. Food & Drug Administration (FDA) for use of the system in screening applications for women with dense breast tissue. A unanimous vote by the FDA's radiological devices panel recommended approval in April, paving the way for U-Systems' ABUS device to become the first and only ultrasound system to obtain FDA approval for breast cancer screening indications.

U-Systems' path to success can also be attributed to its efforts to raise awareness of healthcare professionals and patients to the issues surrounding breast density. The company's dedication and efforts have attracted more than $30 million in additional venture funding since 2007, which has enabled it to further expand investments in research and development. The company has continued to provide its customers with innovative technology upgrades and enhancements for the somo-v system.

With every successive upgrade, U-System has increased the revenue potential of its unique technology while enhancing effectiveness and ease of use. In recognition of its strategic excellence and commitment to rapidly meeting the needs in the end-user market, the company is the worthy recipient of the 2012 North American Entrepreneurial Company of the Year Award in breast imaging.

Each year, Frost & Sullivan presents this award to the company that has demonstrated entrepreneur spirit by devising a strong growth strategy and robustly implementing it. The award recognizes the recipient's strength in terms of innovation in products/technologies, leadership in customer value and speedy response to market needs.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About U-Systems, Inc.

Located in the heart of Silicon Valley, U-Systems, Inc. is establishing the standard for breast ultrasound screening. U-Systems develops 3D ultrasound products specifically designed for earlier detection of breast cancer. As the leader in automated breast ultrasound technology, U-Systems created the somo-v® Platinum Automated Breast Ultrasound (ABUS) System to address the limitations of hand-held breast ultrasound.  Incorporating the latest in proprietary hardware and software technologies, the somo-v Platinum is the result of 10 years of research and development. The somo-v Platinum and somo-VIEWer Advanced 3D Workstation were specifically designed to increase breast cancer detection in women with dense breast tissue where the effectiveness of screening mammography has known limitations.

For more information about U-Systems, visit

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:        Gain access to visionary innovation

Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Recognizes Terso Solutions, Inc. with 2012 Best Practices Award
2. Frost & Sullivan Lauds MobileHelp for Its Outstanding Products and Performance in the North American Health Technology Market
3. Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics
4. Increasing Minimal Invasive Surgeries to Boost Adoption of Hybrid Operating Rooms in Europe, Says Frost & Sullivan
5. Frost & Sullivan: Improving Economies in Indonesia and Vietnam Present Strong Growth Potential in Healthcare
6. Lower Operating Expense Augments Digital X-rays Uptake Across Industries, Finds Frost & Sullivan
7. Adoption of Prefillable Syringes Rising, Especially In High-cost Drug Applications to Contain Wastage, Notes Frost & Sullivan
8. Frost & Sullivan Recognizes Secant Medical as a Key Technology Enabler for Medical Implantable Textile Structures Design
9. Somnetics Pioneering CPAP Device Receives the 2012 North American Frost & Sullivan Award for Product Differentiation Excellence
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
Post Your Comments:
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
Breaking Medicine News(10 mins):